Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

Thursday, October 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. has received marketing authorizations from the Ministry of Health of Armenia for its immuno-oncology products, Botvymo® (botensilimab) and Evamplix® (balstilimab). These products are approved for use together in adult patients with microsatellite stable metastatic colorectal cancer who have previously undergone treatment. This marks a significant step for Agenus in expanding its product reach.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agenus receives marketing authorization in Armenia.
  • BOT and BAL are approved for a specific cancer treatment.
  • The combination therapy targets previously treated patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
3.1%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Botensilimab
Phase 2 · Early Rectal Cancer

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases who have previously received ava

Frequently Asked Questions

What products did Agenus receive approval for?

Agenus received approval for Botvymo® (botensilimab) and Evamplix® (balstilimab).

What type of cancer are the approved products targeting?

The products target microsatellite stable metastatic colorectal cancer.

Who are the approved products intended for?

They are intended for adult patients who have previously received treatment.

Which country granted the marketing authorization?

The marketing authorization was granted by Armenia.

ShareAdd on Google
Tags: AGEN Agenus BOT BAL MSS mCRC Armenia
Last updated: Oct 8, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
BotensilimabPhase 2
Early Rectal Cancer →

Catalyst track record

+121%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →